1 |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492 .
|
2 |
HE Y, WANG Y, LUAN F, et al. Chinese and global burdens of gastric cancer from 1990 to 2019[J]. Cancer Med, 2021, 10(10):3461-3473. DOI:10.1002/cam4.3892 .
|
3 |
KERSTEN K, DE VISSER K E, VAN MILTENBURG M H, et al. Genetically engineered mouse models in oncology research and cancer medicine[J]. EMBO Mol Med, 2017, 9(2):137-153. DOI:10.15252/emmm.201606857 .
|
4 |
KIM J, KOO B K, KNOBLICH J A. Human organoids: model systems for human biology and medicine[J]. Nat Rev Mol Cell Biol, 2020, 21(10):571-584. DOI:10.1038/s41580-020-0259-3 .
|
5 |
RISBRIDGER G P, LAWRENCE M G, TAYLOR R A. PDX: moving beyond drug screening to versatile models for research discovery[J]. J Endocr Soc, 2020, 4(11): bvaa132. DOI:10.1210/jendso/bvaa132 .
|
6 |
CORRÒ C, NOVELLASDEMUNT L, LI V S W. A brief history of organoids[J]. Am J Physiol Cell Physiol, 2020, 319(1): C151-C165. DOI:10.1152/ajpcell.00120.2020 .
|
7 |
KAMB A. What's wrong with our cancer models?[J]. Nat Rev Drug Discov, 2005, 4(2):161-165. DOI:10.1038/nrd1635 .
|
8 |
CAPONIGRO G, SELLERS W R. Advances in the preclinical testing of cancer therapeutic hypotheses[J]. Nat Rev Drug Discov, 2011, 10(3):179-187. DOI:10.1038/nrd3385 .
|
9 |
VLACHOGIANNIS G, HEDAYAT S, VATSIOU A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378):920-926. DOI:10.1126/science.aao2774 .
|
10 |
SEIDLITZ T, MERKER S R, ROTHE A, et al. Human gastric cancer modelling using organoids[J]. Gut, 2019, 68(2):207-217. DOI:10.1136/gutjnl-2017-314549 .
|
11 |
JABS J, ZICKGRAF F M, PARK J, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations[J]. Mol Syst Biol, 2017, 13(11):955. DOI:10.15252/msb.20177697 .
|
12 |
ABBASI J. Patient-derived organoids predict cancer treatment response[J]. JAMA, 2018, 319(14):1427. DOI:10.1001/jama.2018.3760 .
|
13 |
STEELE N G, CHAKRABARTI J, WANG J, et al. An organoid-based preclinical model of human gastric cancer[J]. Cell Mol Gastroenterol Hepatol, 2019, 7(1):161-184. DOI:10.1016/j.jcmgh.2018.09.008 .
|
14 |
BARKER N, HUCH M, KUJALA P, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro [J]. Cell Stem Cell, 2010, 6(1):25-36. DOI:10.1016/j.stem.2009.11.013 .
|
15 |
YAN H H N, SIU H C, LAW S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening[J]. Cell Stem Cell, 2018, 23(6):882-897.e11. DOI:10.1016/j.stem. 2018.09.016 .
|
16 |
NANKI K, TOSHIMITSU K, TAKANO A, et al. Divergent routes toward wnt and R-spondin niche independency during human gastric carcinogenesis[J]. Cell, 2018, 174(4):856-869.e17. DOI:10.1016/j.cell.2018.07.027 .
|
17 |
GAO M, LIN M, RAO M, et al. Development of patient-derived gastric cancer organoids from endoscopic biopsies and surgical tissues[J]. Ann Surg Oncol, 2018, 25(9):2767-2775. DOI:10.1245/s10434-018-6662-8 .
|
18 |
UKAI S, HONMA R, SAKAMOTO N, et al. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell[J]. Oncogene, 2020, 39(50):7265-7278. DOI:10.1038/s41388-020-01492-9 .
|
19 |
HOLOKAI L, CHAKRABARTI J, BRODA T, et al. Increased programmed death-ligand 1 is an early epithelial cell response to Helicobacter pylori infection[J]. PLoS Pathog, 2019, 15(1): e1007468. DOI:10.1371/journal.ppat.1007468 .
|
20 |
STANGE D E, KOO B K, HUCH M, et al. Differentiated Troy+chief cells act as reserve stem cells to generate all lineages of the stomach epithelium[J]. Cell, 2013, 155(2):357-368. DOI:10.1016/j.cell.2013.09.008 .
|
21 |
XIAO X, CHEN W, WEI Z W, et al. The anti-tumor effect of nab-paclitaxel proven by patient-derived organoids[J]. Onco Targets Ther, 2020, 13:6017-6025. DOI:10.2147/ott.s237431 .
|
22 |
LI J, XU H, ZHANG L, et al. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening[J]. J Cancer Res Clin Oncol, 2019, 145(11):2637-2647. DOI:10.1007/s00432-019-03004-z .
|
23 |
LAUREN P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification[J]. Acta Pathol Microbiol Scand, 1965, 64:31-49. DOI:10.1111/apm.1965.64.1.31 .
|
24 |
BOSMAN F T, CARNEIRO F, HRUBAN R H, et al. WHO classification of tumours of the digestive system[M]. Lyon, France: International Agency for Research on Cancer Press, 2010.
|
25 |
CANCER GENOME ATLAS RESEARCH NETWORK. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517):202-209. DOI:10.1038/nature13480 .
|
26 |
WANG K, YUEN S T, XU J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer[J]. Nat Genet, 2014, 46(6):573-582. DOI:10.1038/ng.2983 .
|
27 |
LO Y H, KOLAHI K, DU Y, et al. A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and non-essential modes of oncogenic transformation[J]. Cancer Discov, 2021, 11(6):1562-1581. DOI: 10.1158/2159-8290.CD-20-1109 .
|
28 |
WANG Y, KIM R, GUNASEKARA D B, et al. Formation of human colonic crypt array by application of chemical gradients across a shaped epithelial monolayer[J]. Cell Mol Gastroenterol Hepatol, 2018, 5(2):113-130. DOI:10.1016/j.jcmgh.2017.10.007 .
|
29 |
WANG X, YAMAMOTO Y, WILSON L H, et al. Cloning and variation of ground state intestinal stem cells[J]. Nature, 2015, 522(7555):173-178. DOI:10.1038/nature14484 .
|
30 |
NAKAGAWA H, FUJITA M. Whole genome sequencing analysis for cancer genomics and precision medicine[J]. Cancer Sci, 2018, 109(3):513-522. DOI:10.1111/cas.13505 .
|
31 |
BARTFELD S, BAYRAM T, VAN DE WETERING M, et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection[J]. Gastroenterology, 2015, 148(1):126-136.e6. DOI:10.1053/j.gastro.2014.09.042 .
|
32 |
NADAULD L D, GARCIA S, NATSOULIS G, et al. Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer[J]. Genome Biol, 2014, 15(8):1-18. DOI:10.1186/s13059-014-0428-9 .
|
33 |
GRAHAM D Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits[J]. Gastroenterology, 2015, 148(4):719-31.e3. DOI:10.1053/j.gastro.2015.01.040 .
|
34 |
BURKITT M D, DUCKWORTH C A, WILLIAMS J M, et al. Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models[J]. Dis Model Mech, 2017, 10(2):89-104. DOI:10.1242/dmm.027649 .
|
35 |
ÖHLUND D, HANDLY-SANTANA A, BIFFI G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer[J]. J Exp Med, 2017, 214(3):579-596. DOI:10.1084/jem.20162024 .
|
36 |
SCHLAERMANN P, TOELLE B, BERGER H, et al. A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro [J]. Gut, 2016, 65(2):202-213. DOI:10.1136/gutjnl-2014-307949 .
|
37 |
SCANU T, SPAAPEN R M, BAKKER J M, et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma[J]. Cell Host Microbe, 2015, 17(6):763-774. DOI:10.1016/j.chom. 2015. 05.002 .
|
38 |
MCCRACKEN K W, CATÁ E M, CRAWFORD C M, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids[J]. Nature, 2014, 516(7531):400-404. DOI:10.1038/nature13863 .
|
39 |
SCHUMACHER M A, FENG R, AIHARA E, et al. Helicobacter pylori-induced sonic hedgehog expression is regulated by NFκB pathway activation: the use of a novel in vitro model to study epithelial response to infection[J]. Helicobacter, 2015, 20(1):19-28. DOI:10.1111/hel.12152 .
|
40 |
WEEBER F, OOFT S N, DIJKSTRA K K, et al. Tumor organoids as a pre-clinical cancer model for drug discovery[J]. Cell Chem Biol, 2017, 24(9):1092-1100. DOI:10.1016/j.chembiol. 2017.06.012 .
|
41 |
FRANCIES H E, BARTHORPE A, MCLAREN-DOUGLAS A, et al. Drug sensitivity assays of human cancer organoid cultures[J]. Methods Mol Biol, 2019, 1576:339-351. DOI:10.1007/7651_2016_10 .
|
42 |
ABERLE M R, BURKHART R A, TIRIAC H, et al. Patient-derived organoid models help define personalized management of gastrointestinal cancer[J]. Br J Surg, 2018, 105(2):e48-e60. DOI:10.1002/bjs.10726 .
|
43 |
DROST J, CLEVERS H. Organoids in cancer research[J]. Nat Rev Cancer, 2018, 18(7):407-418. DOI:10.1038/s41568-018-0007-6 .
|
44 |
HAAG G M. OPPOSITE: Outcome prediction of systemic treatment in esophagogastric carcinoma (OPPOSITE)[EB/OL]. [2019-02-18]. .
|
45 |
WALLASCHEK N, REUTER S, SILKENAT S, et al. Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids[J]. PLoS Pathog, 2021, 17(2): e1009210. DOI:10.1371/journal.ppat.1009210 .
|